Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
Status:
Completed
Trial end date:
2020-03-14
Target enrollment:
Participant gender:
Summary
This study evaluates whether it is safe to administer a peptide vaccine in combination with
pembrolizumab. This study will also evaluate the effects of the combination of the peptide
vaccine and pembrolizumab on the immune system. The investigators will monitor these effects
by performing tests in the laboratory on participants' blood, a lymph node, and tumor
samples.